Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 3
2011 5
2012 4
2013 1
2014 3
2015 5
2016 2
2017 1
2018 1
2020 3
2021 3
2022 3
2023 1
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
Brain metastasis from gastrointestinal cancers: a systematic review.
Esmaeilzadeh M, Majlesara A, Faridar A, Hafezi M, Hong B, Esmaeilnia-Shirvani H, Neyazi B, Mehrabi A, Nakamura M. Esmaeilzadeh M, et al. Among authors: faridar a. Int J Clin Pract. 2014 Jul;68(7):890-9. doi: 10.1111/ijcp.12395. Epub 2014 Mar 25. Int J Clin Pract. 2014. PMID: 24666726 Review.
Behcet's disease: from East to West.
Davatchi F, Shahram F, Chams-Davatchi C, Shams H, Nadji A, Akhlaghi M, Faezi T, Ghodsi Z, Faridar A, Ashofteh F, Sadeghi Abdollahi B. Davatchi F, et al. Among authors: faridar a. Clin Rheumatol. 2010 Aug;29(8):823-33. doi: 10.1007/s10067-010-1430-6. Epub 2010 Mar 31. Clin Rheumatol. 2010. PMID: 20354748 Review.
Generation of immunogenic and tolerogenic clinical-grade dendritic cells.
Kalantari T, Kamali-Sarvestani E, Ciric B, Karimi MH, Kalantari M, Faridar A, Xu H, Rostami A. Kalantari T, et al. Among authors: faridar a. Immunol Res. 2011 Dec;51(2-3):153-60. doi: 10.1007/s12026-011-8255-5. Immunol Res. 2011. PMID: 22105838 Free PMC article. Review.
A phase 1 proof-of-concept study evaluating safety, tolerability, and biological marker responses with combination therapy of CTLA4-Ig and interleukin-2 in amyotrophic lateral sclerosis.
Thonhoff JR, Beers DR, Zhao W, Faridar A, Thome A, Wen S, Zhang A, Wang J, Appel SH. Thonhoff JR, et al. Among authors: faridar a. Front Neurol. 2024 Jun 10;15:1415106. doi: 10.3389/fneur.2024.1415106. eCollection 2024. Front Neurol. 2024. PMID: 38915796 Free PMC article.
33 results